Merel Gijsen

780 total citations
17 papers, 540 citations indexed

About

Merel Gijsen is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Merel Gijsen has authored 17 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Merel Gijsen's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Merel Gijsen is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Merel Gijsen collaborates with scholars based in United Kingdom, United States and Italy. Merel Gijsen's co-authors include Anthony Kong, Adrian L. Harris, Ioannis Roxanis, Banafshé Larijani, Peter J. Parker, Tim Perera, Peter King, Jacek Capala, Gabriela Krämer-Marek and Jannie Borst and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and PLoS Biology.

In The Last Decade

Merel Gijsen

17 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Merel Gijsen United Kingdom 9 364 222 212 66 59 17 540
Elza Friedländer Hungary 7 370 1.0× 293 1.3× 223 1.1× 47 0.7× 38 0.6× 7 530
Elena Bonazzoli United States 15 319 0.9× 122 0.5× 147 0.7× 99 1.5× 76 1.3× 31 531
Marta Bellone Italy 11 243 0.7× 76 0.3× 147 0.7× 47 0.7× 69 1.2× 18 446
A. Lambiase Italy 17 613 1.7× 146 0.7× 297 1.4× 181 2.7× 102 1.7× 55 899
Olga Ab United States 11 577 1.6× 398 1.8× 190 0.9× 42 0.6× 73 1.2× 23 776
David Egging Netherlands 14 312 0.9× 322 1.5× 234 1.1× 46 0.7× 85 1.4× 22 723
Chirayu Shah United States 10 298 0.8× 164 0.7× 156 0.7× 67 1.0× 22 0.4× 19 551
Federica Giugliano Italy 13 535 1.5× 271 1.2× 158 0.7× 182 2.8× 66 1.1× 32 708
Frederike Bensch Netherlands 12 373 1.0× 360 1.6× 101 0.5× 135 2.0× 51 0.9× 25 585
FO Smith United States 9 281 0.8× 189 0.9× 426 2.0× 31 0.5× 173 2.9× 15 1.1k

Countries citing papers authored by Merel Gijsen

Since Specialization
Citations

This map shows the geographic impact of Merel Gijsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merel Gijsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merel Gijsen more than expected).

Fields of papers citing papers by Merel Gijsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Merel Gijsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merel Gijsen. The network helps show where Merel Gijsen may publish in the future.

Co-authorship network of co-authors of Merel Gijsen

This figure shows the co-authorship network connecting the top 25 collaborators of Merel Gijsen. A scholar is included among the top collaborators of Merel Gijsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Merel Gijsen. Merel Gijsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Gijsen, Merel, et al.. (2017). The Role Of Companion Diagnostics In HTAS Of Drugs In France, Germany And The UK. Value in Health. 20(9). A471–A471. 1 indexed citations
2.
McKendrick, Jan, Merel Gijsen, Casey Quinn, Beth Barber, & Zhongyun Zhao. (2016). Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries. Journal of Medical Economics. 19(6). 587–595. 2 indexed citations
3.
Barlev, Arie, et al.. (2015). Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom. Health and Quality of Life Outcomes. 13(1). 181–181. 12 indexed citations
4.
Generali, Daniele, Gabriela Krämer-Marek, Merel Gijsen, et al.. (2014). ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5(16). 6633–6646. 68 indexed citations
5.
Generali, Daniele, Gabriela Krämer-Marek, Merel Gijsen, et al.. (2014). Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5(15). 5934–5949. 50 indexed citations
6.
Kooij, Bert van de, Inge Verbrugge, Evert de Vries, et al.. (2013). Ubiquitination by the Membrane-associated RING-CH-8 (MARCH-8) Ligase Controls Steady-state Cell Surface Expression of Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) Receptor 1*. Journal of Biological Chemistry. 288(9). 6617–6628. 74 indexed citations
7.
Canonici, Alexandra, Merel Gijsen, Maeve Mullooly, et al.. (2013). Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 4(10). 1592–1605. 137 indexed citations
8.
Krämer-Marek, Gabriela, Merel Gijsen, Dale O. Kiesewetter, et al.. (2012). Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model. Journal of Nuclear Medicine. 53(4). 629–637. 30 indexed citations
9.
Capala, Jacek, Anthony Kong, Gabriela Krämer-Marek, & Merel Gijsen. (2012). Reply: PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model. Journal of Nuclear Medicine. 53(10). 1655–1656. 3 indexed citations
10.
Gijsen, Merel, et al.. (2012). 24P PTPN9 is a Negative Regulator of HER3 Phosphorylation and a Prognostic Biomarker in HER2 Positive Breast Cancer. Annals of Oncology. 23. ii21–ii22. 1 indexed citations
11.
12.
Gijsen, Merel, et al.. (2011). Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib. Cancer Research. 71(8_Supplement). 1737–1737. 1 indexed citations
13.
Gijsen, Merel, et al.. (2011). Abstract 2235: FRET assay to assess EGFR/HER2 dimerization in cancer cell lines. Cancer Research. 71(8_Supplement). 2235–2235. 1 indexed citations
14.
Gijsen, Merel, P King, Tim Perera, et al.. (2010). UPREGULATION OF ADAM17 PROTEASE AND HER LIGANDS THROUGH A PKB NEGATIVE FEEDBACK LOOP MEDIATES ACQUIRED RESISTANCE TO TRASTUZUMAB IN HER2 OVEREXPRESSED BREAST CANCER. Annals of Oncology. 21. 51–51. 3 indexed citations
15.
Gijsen, Merel, Peter King, Tim Perera, et al.. (2010). HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. PLoS Biology. 8(12). e1000563–e1000563. 109 indexed citations
16.
Gijsen, Merel, P King, Timothy Perera, et al.. (2010). Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer. Breast Cancer Research. 12(S1). 5 indexed citations
17.
Turnhout, Mark C. van, et al.. (2008). Quantitative description of collagen structure in the articular cartilage of the young and adult equine distal metacarpus. Animal Biology. 58(4). 353–370. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elza Friedländer Breakdown of academic impact, for papers by Elena Bonazzoli Breakdown of academic impact, for papers by Marta Bellone Breakdown of academic impact, for papers by A. Lambiase Breakdown of academic impact, for papers by Olga Ab Breakdown of academic impact, for papers by David Egging Breakdown of academic impact, for papers by Chirayu Shah Breakdown of academic impact, for papers by Federica Giugliano Breakdown of academic impact, for papers by Frederike Bensch Breakdown of academic impact, for papers by FO Smith
Rankless by CCL
2026